文献速递心脑血管急症

冠状动脉CT血管造影与血管内超声指导PCI的比较

Coronary CT Angiography versus Intravascular Ultrasound Guidance for PCI.
PubMed 文献 · N Engl J Med · 2026-11-01
一句话结论CCTA指导PCI在12个月靶血管失败方面不劣于IVUS指导PCI,风险差异-0.42个百分点(95%CI -2.82至1.99)。

这项研究者发起的国际开放标签随机非劣效性试验,纳入1105例有血运重建指征、至少一处心外膜病变直径狭窄>70%且CCTA-derived FFR≤0.80的患者,1:1随机至CCTA指导或IVUS指导PCI策略。主要终点12个月靶血管失败(心源性死亡、靶血管心梗或缺血驱动靶血管血运重建复合终点)在CCTA组4.1%、IVUS组4.6%,风险差异-0.42个百分点(95%CI -2.82至1.99),非劣效P<0.001,优效P=0.73。CCTA组6例、IVUS组9例发生临床操作并发症。

要点

  • 纳入标准:有血运重建临床指征、至少一处心外膜病变直径狭窄>70%、CCTA-derived FFR≤0.80。
  • 主要终点12个月靶血管失败:CCTA组4.1%(23/556) vs IVUS组4.6%(25/549),风险差异-0.42个百分点(95%CI -2.82至1.99)。
  • 非劣效界值4.5个百分点,非劣效P<0.001;优效性P=0.73,未显示优效。
  • 临床操作并发症:CCTA组6例,IVUS组9例。
  • 中位年龄65岁,女性21.7%。

适用人群与场景

  • 有血运重建临床指征、至少一处心外膜病变直径狭窄>70%、CCTA-derived FFR≤0.80的患者。
  • 研究为国际、研究者发起、开放标签、随机、非劣效性试验,终点裁决设盲。

诊断标准与关键阈值

  • 靶血管失败定义:心源性死亡、靶血管心肌梗死或缺血驱动靶血管血运重建的复合终点,评估时间12个月。
  • 非劣效界值:绝对风险差异4.5个百分点。
  • 入组病变标准:至少一处心外膜病变直径狭窄>70%且CCTA-derived FFR≤0.80。

处置流程与药物剂量

  • 干预策略:CCTA指导PCI vs IVUS指导PCI,随机1:1分配。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:研究者发起的国际、开放标签、随机、非劣效性试验,终点裁决设盲,预设 hierarchical testing strategy 检验优效性。
  • 样本量与中心数:共1105例随机(CCTA组556例,IVUS组549例);中心数原文未提及。
  • 人群特征:中位年龄65岁,女性21.7%。
  • 主要终点:12个月靶血管失败CCTA组4.1%(23例) vs IVUS组4.6%(25例),风险差异-0.42个百分点(95%CI -2.82至1.99),非劣效P<0.001,优效P=0.73。
  • 关键次要终点:原文未提及。
  • 不良事件:临床操作并发症CCTA组6例,IVUS组9例。

证据类型、等级与局限

  • 证据类型:随机对照试验(RCT),非劣效性设计,开放标签,终点裁决设盲。
  • 证据等级或推荐强度:原文未提及。
  • 局限:开放标签设计;单盲仅终点裁决;随访12个月;由GE HealthCare和Heartflow资助;中心数未报告。

对床旁实践的改变

  • 对于有血运重建指征、至少一处心外膜病变直径狭窄>70%且CCTA-derived FFR≤0.80的患者,CCTA指导PCI可作为IVUS指导PCI的替代策略,12个月靶血管失败风险不劣于IVUS指导。
  • 不能将本研究结果外推至不符合入组标准(如直径狭窄≤70%或CCTA-derived FFR>0.80)的患者。
  • 原文未提及CCTA指导PCI相比IVUS在操作细节或资源利用上的具体差异。

指南或共识出处

  • P4 ClinicalTrials.gov number, NCT05253677.

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) improves clinical outcomes. Coronary computed tomographic angiography (CCTA) provides anatomical and physiological information before cardiac catheterization that may enable PCI planning. Data regarding the use of CCTA-guided PCI as compared with IVUS-guided PCI with respect to clinical outcomes are lacking.

METHODS: In this investigator-initiated, international, open-label, randomized, noninferiority trial with blinded end-point adjudication, we randomly assigned patients with a clinical indication for revascularization, at least one epicardial lesion with a diameter stenosis of more than 70%, and a fractional flow reserve derived from CCTA of 0.80 or less in a 1:1 ratio to a CCTA-guided or IVUS-guided PCI strategy. The primary end point was target-vessel failure, defined as a composite of death from cardiac causes, target-vessel myocardial infarction, or ischemia-driven target-vessel revascularization, at 12 months. The noninferiority margin for the absolute risk difference was 4.5 percentage points, with a prespecified hierarchical testing strategy for superiority.

RESULTS: A total of 1105 patients underwent randomization: 556 to the CCTA-guided PCI group and 549 to the IVUS-guided PCI group. The median age of the patients was 65 years, and 21.7% were women. At 12 months, target-vessel failure had occurred in 23 patients (4.1%) in the CCTA-guided PCI group and in 25 patients (4.6%) in the IVUS-guided PCI group (risk difference, -0.42 percentage points; 95% confidence interval, -2.82 to 1.99; P<0.001 for noninferiority; P = 0.73 for superiority). A total of 6 patients in the CCTA-guided PCI group and 9 patients in the IVUS-guided PCI group had clinical procedural complications.

CONCLUSIONS: A CCTA-guided PCI strategy was noninferior to IVUS-guided PCI with respect to target-vessel failure at 12 months. (Funded by GE HealthCare and Heartflow; P4 ClinicalTrials.gov number, NCT05253677.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Collet C, Mizukami T, Bouisset F, et al. Coronary CT Angiography versus Intravascular Ultrasound Guidance for PCI. N Engl J Med. 2026. PMID: 42969897. doi:10.1056/NEJMoa2610771

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。